Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation

In solid organ transplantation, ischemia/reperfusion (IR) injury during organ procurement, storage and reperfusion is an unavoidable detrimental event for the graft, as it amplifies graft inflammation and rejection. Intracellular mitogen-activated protein kinase (MAPK) signaling pathways regulate in...

Full description

Saved in:
Bibliographic Details
Main Authors: Giuseppe Vassalli, Giuseppina Milano, Tiziano Moccetti
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Journal of Transplantation
Online Access:http://dx.doi.org/10.1155/2012/928954
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832558104971051008
author Giuseppe Vassalli
Giuseppina Milano
Tiziano Moccetti
author_facet Giuseppe Vassalli
Giuseppina Milano
Tiziano Moccetti
author_sort Giuseppe Vassalli
collection DOAJ
description In solid organ transplantation, ischemia/reperfusion (IR) injury during organ procurement, storage and reperfusion is an unavoidable detrimental event for the graft, as it amplifies graft inflammation and rejection. Intracellular mitogen-activated protein kinase (MAPK) signaling pathways regulate inflammation and cell survival during IR injury. The four best-characterized MAPK subfamilies are the c-Jun NH2-terminal kinase (JNK), extracellular signal- regulated kinase-1/2 (ERK1/2), p38 MAPK, and big MAPK-1 (BMK1/ERK5). Here, we review the role of MAPK activation during myocardial IR injury as it occurs during heart transplantation. Most of our current knowledge regarding MAPK activation and cardioprotection comes from studies of preconditioning and postconditioning in nontransplanted hearts. JNK and p38 MAPK activation contributes to myocardial IR injury after prolonged hypothermic storage. p38 MAPK inhibition improves cardiac function after cold storage, rewarming and reperfusion. Small-molecule p38 MAPK inhibitors have been tested clinically in patients with chronic inflammatory diseases, but not in transplanted patients, so far. Organ transplantation offers the opportunity of starting a preconditioning treatment before organ procurement or during cold storage, thus modulating early events in IR injury. Future studies will need to evaluate combined strategies including p38 MAPK and/or JNK inhibition, ERK1/2 activation, pre- or postconditioning protocols, new storage solutions, and gentle reperfusion.
format Article
id doaj-art-700cfe0e528c4e15a6f8dd3815ce07ad
institution Kabale University
issn 2090-0007
2090-0015
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Journal of Transplantation
spelling doaj-art-700cfe0e528c4e15a6f8dd3815ce07ad2025-02-03T01:33:09ZengWileyJournal of Transplantation2090-00072090-00152012-01-01201210.1155/2012/928954928954Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart TransplantationGiuseppe Vassalli0Giuseppina Milano1Tiziano Moccetti2Fondazione CardioCentro Ticino, Via Tesserete, 6900 Lugano, SwitzerlandDepartment of Cardiovascular Surgery, University of Lausanne Medical Center, Av. du Bugnon, 1011 Lausanne, SwitzerlandFondazione CardioCentro Ticino, Via Tesserete, 6900 Lugano, SwitzerlandIn solid organ transplantation, ischemia/reperfusion (IR) injury during organ procurement, storage and reperfusion is an unavoidable detrimental event for the graft, as it amplifies graft inflammation and rejection. Intracellular mitogen-activated protein kinase (MAPK) signaling pathways regulate inflammation and cell survival during IR injury. The four best-characterized MAPK subfamilies are the c-Jun NH2-terminal kinase (JNK), extracellular signal- regulated kinase-1/2 (ERK1/2), p38 MAPK, and big MAPK-1 (BMK1/ERK5). Here, we review the role of MAPK activation during myocardial IR injury as it occurs during heart transplantation. Most of our current knowledge regarding MAPK activation and cardioprotection comes from studies of preconditioning and postconditioning in nontransplanted hearts. JNK and p38 MAPK activation contributes to myocardial IR injury after prolonged hypothermic storage. p38 MAPK inhibition improves cardiac function after cold storage, rewarming and reperfusion. Small-molecule p38 MAPK inhibitors have been tested clinically in patients with chronic inflammatory diseases, but not in transplanted patients, so far. Organ transplantation offers the opportunity of starting a preconditioning treatment before organ procurement or during cold storage, thus modulating early events in IR injury. Future studies will need to evaluate combined strategies including p38 MAPK and/or JNK inhibition, ERK1/2 activation, pre- or postconditioning protocols, new storage solutions, and gentle reperfusion.http://dx.doi.org/10.1155/2012/928954
spellingShingle Giuseppe Vassalli
Giuseppina Milano
Tiziano Moccetti
Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation
Journal of Transplantation
title Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation
title_full Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation
title_fullStr Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation
title_full_unstemmed Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation
title_short Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation
title_sort role of mitogen activated protein kinases in myocardial ischemia reperfusion injury during heart transplantation
url http://dx.doi.org/10.1155/2012/928954
work_keys_str_mv AT giuseppevassalli roleofmitogenactivatedproteinkinasesinmyocardialischemiareperfusioninjuryduringhearttransplantation
AT giuseppinamilano roleofmitogenactivatedproteinkinasesinmyocardialischemiareperfusioninjuryduringhearttransplantation
AT tizianomoccetti roleofmitogenactivatedproteinkinasesinmyocardialischemiareperfusioninjuryduringhearttransplantation